iauae au?eaaaiinoe ia?ao oeacaiiuie a?oiiaie iie ia ia-
ia?o?eee (16).
A iaaieuoii enneaaiaaiee Erem T. n niaaoi?aie n?aaieee
?acoeuoaou eo?aaie oa?aiee aac (a?oiia A — 20 aieuiuo) e a ni-
?aoaiee n iaiea?iiaoii (90 ia ea?aua 4 iaaaee) (a?oiia A - 29
aieuiuo) (11). ?a?ac 3 ianyoa io ia?aea ea?aiey io?aaeenu a
aiaeuaaoeeao 22% ec a?oiiu A e 7% ec A. ?a?ac 6 ianyoaa neooa-
oey ia eciaieeanu, a a?oiia A io?aaeenu a iaacaieeaaiee 12%
i?ioea 8% a a?oiia A, a ?a?ac 12 ianyoaa a iiaoi?iie eo?aaie
oa?aiee eniuouaaee iaiaoiaeiinou 33% aieuiuo a?oiiu A e
oieuei 10% a?oiiu A. Aiaeuaaoeee o?aaiaaeenu niioaaonoaaiii
20% e 15% aieuiui yoeo a?oii.
Iaiaa anao eco?aia yooaeoeaiinou eaaia?iiaoa i?e iaoa-
noacao ?aea iiei?iie ?aeacu. A enneaaiaaiee Diel I.J. n niaaoi-
?aie o?anoaiaaee 462 ?aiuei, ?acaaeaiiua ia o?e a?oiiu. 153
iaoeaioeai aaiaeee eaaia?iiao a aica 2 ia ea?aua 4 iaaaee a
oa?aiea ai 2-o eao; 152 iaoeaioeai aai aaiaeee a aica 6 ia a?a-
iany?ii, a eiio?ieuiay a?oiia (157 ?aeiaae) iieo?aea ieaoaai
(8). Au?eaaaiinou o anao aieuiuo, iieo?a?ueo eaaia?iiao, ni-
noaaeea 774,3 aiy, a a eiio?iea iia ?aaiyeanu 741,7 aiyi. Ec
iniaaiiinoae enneaaiaaiey — au?eaaaiinou iiauneeanu a
a?oiia iaoeaioie n iyaeioeaiiuie iaoanoacaie iinea 6 iany-
oaa ea?aiey. Ea?anoai ?ecie auei oai auoa, ?ai auea auoa
aica aaiaeiiai eaaia?iiaoa.
Oaeei ia?acii, a ioiioaiee yooaeoeaiinoe ea?aiey iaoa-
noacia ?aea iiei?iie ?aeacu a einoe eee iiooieu-annioee?i-
aaiiie aeia?eaeuoeaiee iaeucy ioaaou i?aaii?oaiea eaeiio-ee-
ai iaiiio aenoinoiiaoo e ii niaaoo aieoi?a Herbert Fleisch nea-
aoao auae?aou iaeaieaa oaiaiue ioou aaaaaiey i?aia?aoa —
ia?i?aeuii a?aaiaaii eee aioo?eaaiii a?aiany?ii (13).
Ia?aeaai e oiene?aneei ?aaeoeyi. A ia?aua aie i?eaia
eeia?iiaoa ii?ao aicieeioou aea?ay, eioi?ay a iineaao?uai
naiinoiyoaeuii i?ioiaeo.
Iaiea?iiaoo i?enou aieaa oe?ieee niaeo? oiene?aneeo ?a-
aeoee: o o?aoe aieuiuo ioia?aaony a?eiiiiiaiaiue neia?ii
aeeoaeuiinou? ai 24 ?ania, oneeaiea aiee a einoyo io 1 ai 3 no-
oie o 16% (5), ieaeaee ia ?aiieo oacao ea?aiey (3,23), a?aiai-
iay ei?iay nuiu, cia?eoaeuii ?a?a oioiioa e ?aioa.
Ana yoi iaoneiaeaii oai, ?oi iaiea?iiao e eaaia?iiao eiao-
oe?o?o iiauoaiea a nuai?ioea e?iae niaa??aiey iiooieu-iae-
?ioece?o?uaai oaeoi?a -
?
e eioa?eaeeeia-6, eioi?ua niiniano-
ao?o iiauoaie? oaiia?aoo?u e ieaeaee. Iaiea?iiao, ii ia
eeia?iiao, o?anoaoao a aeoeaaoee O-eeioioeoia. A oi ?a a?aiy
eaaia?iiao, ianiio?y ia oi, ?oi oae?a ioiineony e acioniaa??a-
uei aenoinoiiaoai, ia aucuaaao O-eeaoi?iie ?aaeoee (24).
Iioaioeaeuiia i?aeiouanoai iaiea?iiaoa — a ?aaeinoe
aaaaaiey, eiaaa oeeeu iiaoo niaiaaaou n aeceoii e a?a?o aey oe-
ieioa?aiee, iaiaei iiiaiiany?iay eiooceiiiay oa?aiey ainoa-
oi?ii ai?iaa (20). A oi ?a a?aiy ea?aiea eeia?iiaoii caiaoii
aaoaaea; i?e?ai ia?i?aeuiay oi?ia ai?i?a aioo?eaaiiie. Ii
iaoaio iiaie? i?e ino?ie aeia?eaeuoeaiee oaeaniia?acii ia-
?eiaou ea?aiea n aioo?eaaiiuo eiuaeoee eeia?iiaoa, a caoai
ii?ii ia?aoiaeou ia ia?i?aeuio? oi?io. Aa?ii oae?a ioia-
oeou oi?ioo? ia?aiineiinou aieuiuie aeeoaeuiiai ea?aiey ia-
?i?aeuiie oi?iie eeia?iiaoa.
Oaeei ia?acii, caee??ay ?anniio?aiea eia?ueony naaaa-
iee i eeeie?aneii eniieuciaaiee aenoinoiiaoia, ii?ii naa-
eaou auaia, ?oi eeia?iiao, iaiea?iiao e eaaia?iiao iaeiaeiai
yooaeoeaiu eae aey ea?aiey iiooieu-annioee?iaaiiie aeia?-
eaeuoeaiee, oae e iaoanoacia ?aea iiei?iie ?aeacu. I?aaii?-
oeoaeuiaa oio, eioi?ue aieaa oaiaai aey aaiiie aieuiie e aucu-
aaao iaiuoa iiai?iuo ?aaeoee.
Литература
1. Комаров Ф.И., Коровкин Б.Ф.Биохимические показате-
ли в клинике внутренних болезней.// Москва. — МЕД-
пресс. — 2000. — 158-160.
2.. Ali S.M., Esteva F.J., .Hortobagyi G., Henick K. et al. Safety
of longterm use of bisphosptonates in cancer patients.//
ASCO. — 1998. — 168.
3. Adami S., Bhalla A.K., Dorizzi R. et al. The acute-phase
response after bisphosphonate administration //Calcif. Tissue.
Int. — 1987. — 41. — 326-331.
4. Blomer L.J.M.J. History of bisphosphonates: Discovery and
history of the nonmedied uses of bisphosphonates.// 111-
124.
5. Costa L., Coleman R., Curley E. et al. Dose intense therapy of
bone metastases with pamidronate.// ASCO. — 1998. — 216.
6. Crohns C.A., Untch M., Konecny G. Different bisphospho-
nates have direct cytotoxic effects on three breast cancer cell
lines and fresh breast cancer tumor tissue.// ASCO. — 2000. —
P.2. — 2005.
7. Costa L., Demers L., Oliveira A. et al. Biochemical evaluation
of different X-ray patterns of bone metastases:A prospective
study/ASCO 2001/1711/
8. Diel I.J., Lichiniser M.R., Body J.J. et al. Improvement of
bone pain, quality of life and survival time of breast cancer
patients with metastatic bone disease treated with intravenous
ibandronate //ECCO. — 1999. — 269.
9. Diel I.J., Solomayer E.F., Costa S.D. et al. Reduction in new
metastases in breast cancer with adjuvant clodronate treatment
//N. Engl J. Med. — 1998. — 339. — 357-363.
10. Dempster D.W./New concepts in bone remodeling /In
Dynamics of bone and cartilage metabolism/London: Acade-
mic Press/261-273.
11. Erem T., Koc M., Polat P. et al/The comparison of radiother-
apy and radiotherapy plus pamidronat on pain palliation of
metastatic bone disease/ECCO 1999/1489.
12. Fischer C., Neudert M., Krempien B. et al/Ibandronic acid
prevents the development and inducea remission of bone
metastases in a nude rat model of human breast cancer/ASCO
2001/332.
13. Fleisch H./Bisphosphonates in bone disease/Academic Press
2000/88-110.
14. Green J.R., Muller K., Jaeggi K.A. / Preclinical pharmacolo-
gy of CGP 42'446,a new, potent, heterocyclic bisphosphonate
compound/J.Bone Miner.Res.,9/745-751.
15. Hortobagyi G., Theriault R.L., Lipton A. et al/Long-term pre-
vention of skeletal complicationa of metastatic breast cancer
with pamidronate /J.Clin.Oncol 1998/16/2038-2044
16. Hultborn R., Gundesen S., Ryden S. et al/Efficacy of
pamidronate in breast cancer with bone metastases:a random-
ized, double-blind placebo-controlled multicenter study/Fnti-
cancer Res.1999/19/3383-3392.
17. Kanis J.A., Powles T., A.H. G.Paterson et al/Clodronate
decreases the frequency of skeletal metastasesin women with
breast cancer/Bone 1996/19/663-667.
18. Lipton A., Hortobadyi G., Simeone J. et al/Progression of
bone metastases in breast cancer patients receiving
pamidronate/ASCO 1998/469.
19. Laitinen R., Patronen A., Harju P. et al/Timing of food intake
has a marked effect on the biovailability of clodronate/ Bone
2000 /27/293-296.
20. McCloskey E.V., Julian G.F., Kanis J.A./The clinical and cost
considerations of bisphosphonates in preventing bone compli-
cations in patients with metastatic breast cancer or multiple
myeloma/Drugs 2001/61/1253-1274.
21. Parfitt J.T./Calcium homeostasis/Handbook of experimental
pharmacology of bone/V.107/165.
22. Paterson A., Powles T., Kanis J. et al/Doubl-blind controlled
trial of oral clodronate in patients with bone metastases from
breast cancer /J.Clin.Oncol.1993/11/59-65.
23. Pecherstorfer V., Jilch R., Sauty A. et al/ Effect of first treat-
ment with aminobisphosphonateas pamidronate and iban-
dronate on circulating lymphocyte subpopulations/J.Bone
Miner Res 2000/15/147-154.
24. Pecherstorfer M., Hammerl B., Jilch R. et al/Effects of the bis-
phosphonates pamidronate, clodronate and ibandronate on
CD 69, an early T-lymphocyte activation marker/ASCO
1998/1719.
570
Антология научных публикаций
